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Abstract: 
Schizophrenia is a heterogenous neurodevelopmental disorder involving the 
convergence of a complex and dynamic bidirectional interaction of genetic 
expression and the accumulation of prenatal and postnatal environmental risk 
factors. The development of the neural circuitry underlying social, cognitive and 
emotional domains requires precise regulation from molecular signalling pathways, 
especially during critical periods or “windows”, when the brain is particularly 
sensitive to the influence of environmental input signalling. Many of the brain 
regions involved, and the molecular substrates sub-serving these domains are 
responsive to life-long microbiota-gut-brain (MGB) axis signalling. This intricate 
microbial signalling system communicates with the brain via the vagus nerve, 
immune system, enteric nervous system, enteroendocrine signalling and production 
of microbial metabolites, such as short-chain fatty acids. Preclinical data has 
demonstrated that MGB axis signalling influences neurotransmission, neurogenesis, 
myelination, dendrite formation and blood brain barrier development, and 
modulates cognitive function and behaviour patterns, such as, social interaction, 
stress management and locomotor activity. Furthermore, preliminary clinical studies 
suggest altered gut microbiota profiles in schizophrenia. Unravelling MGB axis 
signalling in the context of an evolving dimensional framework in schizophrenia may 
provide a more complete understanding of the neurobiological architecture of this 
complex condition and offers the possibility of translational interventions.  
Keywords: Schizophrenia, Psychosis, Microbiota, Microbiome, Gut-brain axis, 
Psychobiotics 
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Introduction: 
Schizophrenia is complex heterogeneous neurodevelopmental disorder with deficits 
across many dimensions. The expression of the underlying genetic vulnerability is 
shaped by a multifaceted combination of prenatal and early postnatal environmental 
factors. These factors sensitise a developing brain and its information processing 
ability, to the subsequent accumulation of additional environmental insults, which 
may overwhelm compensatory capacities during adolescence and emerge as 
psychotic symptoms. Subtle deficits in cognition, social communication and 
functioning are often evident prior to the onset of overt psychotic symptoms and the 
majority of people experience recurring psychotic relapses with variable degrees of 
functional impairment. A precise integrative mechanistic understanding of the 
interaction of genetic and environmental processes across the neurodevelopmental 
trajectory in this condition remains elusive.  
 
The microbial ecosystem is intrinsically linked to human health. Microbiology and 
neuroscience have converged to begin to elucidate the role of microbes in brain 
development and function (Dinan and Cryan, 2013). Microbes communicate with the 
brain via the gut-brain axis encompassing the immune system (Erny et al., 2015), 
tryptophan metabolism (O'Mahony et al., 2015), the hypothalamic-pituitary-adrenal  
(HPA) axis (Sudo et al., 2004), the vagus nerve (Bravo et al., 2011) and by the 
production of microbial metabolites, such as short chain fatty acids (SCFA’s) (Stilling 
et al., 2016b). MGB axis signalling occurs throughout life, but is particularly 
important during the early postnatal period, as the trajectory of early postnatal brain 
development overlaps with the acquisition and expansion of the gut microbiome. 
Advances in preclinical research have revealed that neurotransmission, 
neurogenesis, myelination, dendrite formation and blood brain barrier organisation 
are under the influence of this MGB axis signalling system. At the behavioural level 
MGB axis signalling modulates cognitive function and patterns related to social 
interaction, locomotor activity and stress management.  
 
Precisely determining the subtle complexities in gut microbiota acquisition and 
development and corresponding signalling via the MGB axis across the 
neurodevelopmental stages in schizophrenia is an exciting and evolving area of 
neuroscience research. Furthermore, unravelling microbiota-diet and microbiota-
drug interactions could lead to clinical benefits. Navigating the emerging field of 
psychiatric microbiome research may yield novel insights into individual variations 
and perhaps enable the development of new interventions for certain dysregulated 
domains in psychotic disorders. This review synthesizes the preclinical and emerging 
clinical evidence implicating the microbiome in schizophrenia. 
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Maturation of gut microbiota 
The evolutionary transition from unicellular to multicellular organization occurred 
approximately 3 to 3.5 billion years ago (Grosberg and Strathmann, 2007). This co-
evolution has shaped evolving phenotypes in all life forms and resulted in an 
interlinked physiology between microbe and man. The human body contains as 
many bacterial cells as human cells, with a total mass of 0.2 kg (Sender and Fuchs, 
2016). The majority of these microbes reside in the gastro-intestinal tract (GIT). This 
microbial ecosystem, regarded as an extra, albeit mutable organ (Clarke et al., 2014), 
varies in spatial organization and localization along the GIT, with low concentrations 
transiting from the ileum to the cecum of about 108 bacteria per gram to 1011 bacteria 
per gram in the stool (Sender et al., 2016). Thousands of new human microbiome 
species are being discovered (Forster et al., 2019, Pasolli et al., 2019) and while 
dominated by bacteria, other microbes such as viruses and bacteriophages, protozoa, 
archaea and fungi are also present (Lankelma et al., 2015). In terms of bacterial 
phyla composition, as measured by 16S rRNA gene sequencing and metagenomic 
shotgun sequencing of fecal samples, Firmicutes, Actinobacteria, and Bacteroidetes 
dominate, with lower relative abundances of Verrucomicrobia and Proteobacteria 
(Zhernakova et al., 2016). 
 
Due to complex interindividual variation, comprising marked functional redundancy, 
it is difficult to precisely define a typical healthy adult gut microbiota (The Human 
Microbiome Project et al., 2012, Falony et al., 2016, Shanahan and Hill, 2019). 
However, in the gut, high compositional diversity and stability are associated with 
health benefits (Lozupone et al., 2012). Conversely, the impact of a narrowing of gut 
microbiome diversity and its functional repertoire is associated with indices of poor 
health (Vangay et al., 2018, Claesson et al., 2012, Kelly et al., 2016a, Kelly et al., 
2019b). The gut is largely thought to be sterile in utero and colonized during birth 
and postnatally (Perez-Munoz et al., 2017, Bushman, 2019), though the maternal 
microbiota may indirectly exert effects on the developing fetus (Gomez de Aguero et 
al., 2016, Koren et al., 2012). For example, whether inflammatory responses arise as 
a consequence of bacterial translocation to the intrauterine environment during 
periods of excessive maternal gestational stress, resulting in deficits in 
neurodevelopment remains an open question (Chen and Gur, 2019).  
 
Acquisition and expansion of the infant microbiome are key processes in the 
development of a healthy host-microbiome relationship. The gut microbiota in the 
initial days of life is unstable and of low diversity (Arrieta et al., 2014). Multiple 
maternal sources, such as vaginal, skin, oral, and gut communities all contribute to 
the early infant microbiome. However, a few days postpartum, the contribution of 
the vaginal and skin microbiome decreases, with gut strains showing more 
persistence in the infant gut (Ferretti et al., 2018, Yassour et al., 2018). Breast milk 
facilitates transmission of bifidobacterial communities, including bifidobacterial 
phages (Duranti et al., 2017). Microbial diversity increases over the first three to four 
year of life (Fouhy et al., 2019, Yatsunenko et al., 2012). There is a divergence in 
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intestinal microbiome assembly between different birth modes and between preterm 
and full-term infants, with implications for the associated microbial metabolite 
profile (Fouhy et al., 2019, Bokulich et al., 2016, Hill et al., 2017). However, full-term 
C-section infants gradually progress to harbouring a microbiota closely resembling 
full-term spontaneous vaginally delivered infants by week eight of life (Hill et al., 
2017).  
 
The trajectory of early postnatal brain development overlaps with the acquisition and 
reorganization of the gut microbiota (Borre et al., 2014, Chu et al., 2017). A recent 
cohort study in human infants aged 3 to 6 months (n=309) suggested an association 
between infant gut microbiome composition and communication, personal and 
social, and fine motor skills at age three years, mostly driven by taxa within the order 
Clostridiales (Sordillo et al., 2019). A study of normally developing 1-year-olds 
(n=89), identified 3 groups based on their bacterial composition, that differed on the 
Mullen scales of early learning (Carlson et al., 2018). Additionally, higher alpha 
diversity was associated with lower scores on the overall composite score, visual 
reception scale, and expressive language scale at 2 years of age, though there were 
minimal differences in regional brain regions, measured using structural MRI 
(Carlson et al., 2018). However, the physiologically relevant MGB axis signalling 
cascades remain to be sufficiently characterised (Dinan et al., 2018). 
 
C-section alters the gut microbiota, and is associated with asthma, allergies and 
obesity in offspring (Bar-Meir et al., 2019, Yuan et al., 2016, Martinez et al., 2017). 
While obstetric complications are associated with schizophrenia (Cannon et al., 
2002) the link between C-sections and schizophrenia is tenuous (Fond et al., 2017, 
O’Neill et al., 2015). Other important factors that shape the gut microbiome include 
breast- and formula-feeding (Timmerman et al., 2017), antibiotic usage in early life 
(Korpela et al., 2018, Bokulich et al., 2016, Stearns et al., 2017) and malnutrition (St 
Clair et al., 2005, Million et al., 2017). It has yet to be determined whether subtle 
alterations of the gut microbiome at birth and the proceeding early developmental 
phase, for example, by delivery mode, feeding mode, antibiotics, infections and 
stressors combine with other vulnerability factors, to increase the risk of 
schizophrenia (Table 1). 
 
Microbiota, the immune system and schizophrenia 
The gut microbiota performs a critical priming function in the development of the 
neuroimmune system, pivotal for myelination, synaptic pruning, and neuronal 
remodelling (Hoban et al., 2016c, Rea et al., 2016). This neuroimmune signalling 
during the early postnatal developmental stages is an important determinant of 
cognitive function and emotional behaviour (Spencer and Meyer, 2017). Alterations 
in the gut microbiota signature early in life can predispose to immune disorders 
(Penders et al., 2007, Fujimura et al., 2016, Al Nabhani et al., 2019).  
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Immune system alterations are implicated in the pathophysiology of schizophrenia 
(Corvin and Morris, 2014, Schizophrenia Working Group of the Psychiatric 
Genomics, 2014, Feigenson et al., 2014, Muller, 2014, Sekar et al., 2016, Benros et 
al., 2012). It is well established that certain infections increase the risk of 
schizophrenia (Meyer et al., 2009, Brown, 2012). A large epidemiological study 
(n=1,015,447), showed that treatment with anti-infective agents (primarily driven by 
infections treated with antibiotics), were associated with an increased risk of 
schizophrenia by a hazard rate ratio of 1.37 (Kohler et al., 2017, Kohler-Forsberg et 
al., 2018). A genetically programmed subtle alteration in the immune system, in 
combination with a precisely timed pathogen exposure may amplify susceptibility to 
schizophrenia. For example, the timing of maternal immune activation (MIA), 
triggered by prenatal infection may act as a "neurodevelopmental primer" (Meyer, 
2014, Meehan et al., 2016, Meyer et al., 2006, Smith et al., 2007, Knuesel et al., 2014, 
Coiro et al., 2015, Pendyala et al., 2017).  
 
The MIA rodent model displays deficits in social interactions, a tendency toward 
repetitive behaviour and reduced communication and serves as a useful model for 
neurodevelopmental disorders such as schizophrenia and Autism Spectrum Disorder 
(ASD). The commensal Bacteroides fragilis corrected gut permeability dysfunction 
and reversed the deficits in communicative, stereotypic, anxiety-like and 
sensorimotor behaviours in a MIA mouse model (Hsiao et al., 2013). In other ASD 
mouse models, L. reuteri treatment acted in a vagus nerve-dependent manner and 
ameliorated social interaction-induced synaptic plasticity in the ventral tegmental 
area of ASD mice, but not in oxytocin receptor-deficient mice (Sgritta et al., 2019).  
 
In a recent fecal microbiota transplantation (FMT) study, GF mice colonized with 
human ASD microbiota displayed alternative splicing of ASD-relevant genes, social 
and repetitive behavioural abnormalities and altered metabolome profiles compared 
to GF mice transplanted with fecal samples from typically developing children 
(Sharon et al., 2019). Furthermore, administration of microbial metabolites (taurine, 
the metabolic product of cysteate or taurocholic acid, and 5AV, the fermentation 
product of proline - both GABA-A receptor agonists) to a BTBR autism mouse model, 
improved the ASD-like behaviours (Sharon et al., 2019). Taken together, these 
preclinical studies suggest that microbial-based strategies may show promise in 
ameliorating social dysfunction, characteristic of both ASD and schizophrenia.  
 
Complement, Cytokines and Toll-Like Receptors (TLRs) 
A low-grade inflammatory component both peripherally and centrally, in First 
episode psychosis (FEP) individuals (Di Nicola et al., 2013, de Witte et al., 2014), 
including those without medication (Upthegrove et al., 2014, Song et al., 2014) and 
chronic schizophrenia has been demonstrated (Rodrigues-Amorim et al., 2017, 
Miller et al., 2011, Gallego et al., 2018). Individuals exposed to elevated maternal 
levels of anti-inflammatory cytokines were significantly less likely to develop 
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psychosis in adulthood (Allswede et al., 2016), whereas elevated maternal blood 
levels of complement factor C1q increased the risk of psychosis (Severance et al., 
2014). An intriguing translational study implicated dysregulated complement C4 
activity, another component of the classical complement cascade, that recognizes and 
eliminates pathogens and cellular debris (Sekar et al., 2016). This study showed that 
excessive C4 mediated synapse elimination during postnatal development, was 
associated with the development of schizophrenia (Sekar et al., 2016). Among those 
at clinical high risk of developing psychosis, and then converted to psychosis, higher 
levels of plasma pro-inflammatory cytokines at baseline were predictive of steeper 
rates of gray matter reduction in the right prefrontal cortex (PFC) (Cannon et al., 
2015).  
 
However, the source of this low-grade inflammation is not fully known. Whether it 
reflects underlying pathophysiology or is due to other factors such as obesity, 
smoking, antipsychotic use, or stress has yet to be conclusively determined. The gut 
microbiota mediates many of these factors. Indeed, gut inflammation and 
permeability may be a contributing source, at least in subgroups. In a mouse model 
of social disruption, stress altered the gut microbial profile and increased levels of 
the pro-inflammatory cytokine IL-6 (Bailey et al., 2011). It noteworthy that a 
serological surrogate marker of bacterial translocation (soluble CD14) was elevated 
in schizophrenia compared to controls, though there were no differences in the levels 
of lipopolysaccharide binding protein (LBP) (Severance et al., 2013).  
 
Toll-Like Receptors (TLR) are pattern recognition receptors (PRR), which may have 
evolved to control resident beneficial microbes rather than invasive pathogens 
(Bosch, 2014). TLRs recognize microbe-associated molecular patterns and serve as 
molecular communication channels between the gut microbiota and immune system 
homeostasis. TLR4 binds lipopolysaccharide in gram-negative bacteria, whereas 
TLR2 recognizes lipoproteins and peptidoglycans (PGN) from gram-positive 
bacteria, leading to the production of cytokines. Furthermore, TLR’s are able to 
modulate neurodevelopmental processes. TLR2 and TLR4 knockout mice showed 
subtle impairments in behaviour and cognitive functions (Too et al., 2016, Park et al., 
2015). PRR’s, such as TLR2 in the developing brain can recognize bacterial PGN. A 
study in mice, suggested that PGN from commensal bacteria can enter blood and 
cross the BBB during postnatal development in healthy animals (Arentsen et al., 
2017). Furthermore, the PGN-sensing molecules in the developing striatum are 
partially under the influence of the gut microbiota, and knockdown of the PGN-
recognition protein 2 (Pglyrp2) was associated with the development of sex 
dependent changes in social behaviour and alterations in the expression of the ASD 
risk gene c-Met (Arentsen et al., 2017). 
 
Human studies are few, but drug-naïve patients with schizophrenia exhibited an 
increased percentage of TLR4 and TLR5 monocytes and TLR5 T reg/Tact cells 
compared to matched controls, with higher percentages of TLR4 and TLR5 
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monocytes correlating with more severe cognitive deficits (Kéri et al., 2017). There 
are alterations in TLR agonist-mediated cytokine release in whole blood in patients 
with psychosis compared to healthy controls (McKernan et al., 2011). Moreover, 
alterations in the expression of the initial elements of the TLR4 signalling pathway in 
post-mortem PFC samples from psychosis patients have been shown, though may 
have been influenced by antipsychotic treatment status (García-Bueno et al., 2016).  
 
Microbiota and Microglia 
The gut microbiota is also involved in the maturation and activation of microglia 
(Cryan and Dinan, 2015, Erny et al., 2015). In PET studies, subjects at high risk of 
psychosis, and those with schizophrenia showed evidence of altered microglial 
activation compared to healthy controls (Bloomfield et al., 2016, van Berckel et al., 
2008). However, not all studies are consistent (Collste et al., 2017, Holmes et al., 
2016, Notter and Meyer, 2017, Narendran and Frankle, 2016). Interestingly, GF mice 
display underdeveloped and immature microglia in the cortex, corpus callosum, 
hippocampus, olfactory bulb, and cerebellum (Erny et al., 2015). There was an 
upregulation of microglia transcription and survival factors, and downregulation of 
cell activation genes and genes for type 1 IFN receptor signalling compared with 
those isolated from conventionally colonized control mice. These defects were 
partially restored by recolonization with a complex microbiota, and SCFAs reversed 
the defective microglia in absence of complex microbiota (Erny et al., 2015). A recent 
study showed that the prebiotic (inulin) administered to mice for 14-weeks altered 
the gut microbiota and ameliorated stress-induced immune priming in middle-aged 
mice (10 months), while reducing brain infiltration of Ly-6Chi monocytes and 
reversing increases in a subset of activated microglia (Ly-6C+) (Boehme et al., 2019). 
Collectively, these studies suggest that subtle alterations in gut microbiota 
acquisition and development, by regulating neuro-inflammatory processes, may act 
as additional vulnerability factors that predispose to schizophrenia. 
 
Blood Brain Barrier (BBB) 
BBB dysfunction has been associated with psychotic disorders (Pollak et al., 2017). 
Although the direction of causality has not been determined, it has been postulated 
the BBB dysfunction may be linked to disrupted neuronal and synaptic function, 
increased permeability to inflammatory molecules, disrupted glutamate 
homoeostasis, and impaired action of antipsychotics (Pollak et al., 2017). 
Approximately, 30%-40% of patients with velocardiofacial syndrome (22q11 deletion 
syndrome) have schizophrenia (Monks et al., 2014, Schneider et al., 2014). 22q11 is 
associated with haploinsufficiency of the claudin-5 gene, which produces claudin-5, a 
tight junction (TJ) protein, found in endothelial cells forming part of the BBB. 
Greene and colleagues showed that claudin-5 suppression in mice resulted in 
impairments in learning and memory, anxiety-like behaviour and sensorimotor 
gating (and seizures), and that antipsychotic medications dose-dependently 
increased claudin-5 expression in vitro and in vivo (Greene et al., 2018). Further, 
they showed aberrant, discontinuous expression of claudin 5 in the post mortem 
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brains of schizophrenic patients compared to age-matched controls (Greene et al., 
2018).  
 
Preclinical evidence from GF mice suggests that the microbiota can modulate the 
BBB. Exposure of GF adult mice to the fecal microbiota from pathogen-free donors 
decreased BBB permeability (Braniste et al., 2014). Moreover, monocolonization of 
the intestine of GF adult mice with SCFA-producing bacterial strains normalised 
BBB permeability, whilst sodium butyrate was associated with increased expression 
of the TJ protein occludin in the frontal cortex and hippocampus (Braniste et al., 
2014). Intragastric antibiotic treatment of adult mice showed that antibiotic-induced 
gut alterations reduced the expression of claudin and occludin mRNA in the 
hippocampus and increased the expression of TJ protein 1 and occludin mRNA in the 
amygdala (Frohlich et al., 2016). Low dose penicillin administered to mice during the 
perinatal period (1 week before birth to weaning) showed that the antibiotic induced 
gut microbiota alterations, increased cytokine expression in the frontal cortex, 
modified BBB integrity and decreased anxiety-like and social behaviours, including a 
reduced preference for social novelty in the offspring (Leclercq et al., 2017). 
Concurrent supplementation with L. rhamnosus (JB-1) attenuated the penicillin 
induced decrease in social novelty preference behaviour (Leclercq et al., 2017). 
 
Stress sensitivity, the microbiome and schizophrenia 
Environmental stressors act on genetic vulnerabilities to shape the 
neurodevelopmental trajectory in schizophrenia (Table 1). Early life environmental 
insults are particularly important as they sensitive the developing brain. Stressful life 
events can precipitate psychotic symptoms and sensitivity to minor stressful events 
are associated with more intense psychotic experiences in FEP (Reininghaus et al., 
2016b). The interaction of the mediating role of the gut microbiota, stress sensitivity 
and environmental stressors has not been explored in schizophrenia. Stress can 
reshape gut microbiota composition and alter gut barrier permeability (Galley et al., 
2014a, Galley et al., 2014b, Wang and Wu, 2005, O'Mahony et al., 2009, Golubeva et 
al., 2015, Frohlich et al., 2016, Bailey and Coe, 1999, Bailey et al., 2011, Kelly et al., 
2015). Preclinical evidence suggests that the gut microbiota signature acquired and 
maintained during the pivotal early developmental stage may also affect stress 
sensitivity. GF rodents demonstrate abnormal behavioural and neuroendocrine 
responses to stress (Crumeyrolle-Arias et al., 2014, Moloney et al., 2014, Sudo et al., 
2004, Nishino et al., 2013) and the normal development of the HPA axis is 
contingent on microbiota colonisation at specific neurodevelopmental time points 
(Sudo et al., 2004). Furthermore, the expression of anxiety like behaviour in a mouse 
model of early life stress is partially dependent on the gut microbiota (De Palma et 
al., 2015).  
 
Prenatal stress also impacts the gut microbiota with implications for physiological 
outcomes in the offspring (Golubeva et al., 2015). In a mouse model of prenatal 
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stress, maternal stress decreased the abundance of vaginal Lactobacillus, resulting in 
decreased transmission of this bacterium to offspring, which corresponded with 
changes in metabolite profiles involved in energy balance, and with disruptions of 
amino acid profiles in the developing brain (Jasarevic et al., 2015). Human infants of 
mothers with high self-reported stress and high salivary cortisol concentrations 
during pregnancy had significantly higher relative abundances of Proteobacterial 
groups known to contain pathogens and lower relative abundances of lactic acid 
bacteria (Lactobacillus), Actinobacteria and Bifidobacteria (Zijlmans et al., 2015). In 
addition, those infants with altered microbiota composition exhibited a higher level 
of maternally reported infant GI symptoms and allergic reactions, highlighting the 
functional consequences of aberrant colonisation patterns. However, a recent study 
of seventy mothers, did not find any differences in Proteobacteria, Actinobacteria or 
Lactobacilli and psychosocial stress variables (Hechler et al., 2019).  
 
Microbiota and Neurochemistry 
At the cellular level, brain development and function requires a complex and 
coordinated birth, migration and differentiation of both neurons and glia followed by 
synaptic integration and neural circuit formation. Schizophrenia is associated with 
dysregulation of synaptic function and structure (Habela et al., 2016, McGlashan and 
Hoffman, 2000, Faludi and Mirnics, 2011). The gut microbiota plays a role in 
developmental programming of the brain, specifically, synapse maturation and 
synaptogenesis (Diaz Heijtz et al., 2011) (Figure 1). Synaptophysin, a marker of 
synaptogenesis, and PSD 95, a marker of excitatory synapse maturation, were 
decreased in the striatum in GF mice compared to specific pathogen free (SPF) mice 
(Diaz Heijtz et al., 2011). Reduced levels of synaptophysin have been demonstrated 
in the cerebral cortex of post-mortem samples from schizophrenia subjects (Hu et al., 
2015). 
 
Dopaminergic pathways  
Dopaminergic dysfunction is a key pathophysiological process underpinning the 
manifestation of psychotic symptoms (hallucinations and delusions). A primary 
circuit involved in psychosis includes the thalamus and prefrontal cortex feeding into 
the associative striatum. Excessive D2 signalling in the associative striatum appears 
to be critical for the manifestation of psychotic symptoms, with limbic regions such 
as the hippocampus and amygdala connecting to this circuit, contributing to altered 
sensory perception and emotional context (Kesby et al., 2018). Antipsychotics reduce 
psychotic symptoms primarily by blocking D2 but have little impact on negative and 
cognitive symptoms.  
 
Preclinical studies using GF rodents, antibiotics and probiotics have shown that 
dopaminergic circuits are sensitive to changes in gut microbes (Gonzalez-Arancibia 
et al., 2019) (Table 2). GF mice have altered dopaminergic neurotransmission in the 
hippocampus, striatum and the PFC (Diaz Heijtz et al., 2011, Nishino et al., 2013) 
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(Crumeyrolle-Arias et al., 2014). Similarly, antibiotic treated rodents demonstrate 
altered dopamine metabolite levels in the hippocampus, amygdala and striatum 
(Hoban et al., 2016a, Desbonnet et al., 2015). Although unlikely to cross an intact 
BBB in appreciable quantities, it is nonetheless interesting to note from an 
evolutionary interconnectivity perspective, that the gut microbiota plays a role in the 
production of biologically active free catecholamines, including dopamine (Asano et 
al., 2012). Collectively, these preclinical studies, suggest that the dopaminergic 
system, of direct relevance to the pathophysiological trajectory of psychosis, is under 
the partial influence of the gut microbiota. 
 
Glutamatergic and gamma-aminobutyric acidergic (GABA) pathways 
The glutamate hypothesis of schizophrenia implicates hypofunction of signalling 
through NMDA receptors (NMDARs) on inhibitory neurons, leading to disinhibition 
of glutamate neurons, increasing synaptic activity of glutamate, especially in the PFC 
(Moghaddam and Javitt, 2012, Jackson et al., 2004). This proposes that NMDA 
receptors contribute to psychotic symptoms as well as cognitive deficits in 
schizophrenia (Gonzalez-Burgos and Lewis, 2012, Thomas et al., 2017). Indeed, 
NMDA receptor antagonists, such as ketamine can manifest aspects of schizophrenia 
in healthy volunteers, including some of the attentional and memory problems, and 
can exacerbate symptoms in individuals with schizophrenia (Malhotra et al., 1997, 
Breier et al., 1997). Rats that received intraperitoneally injected ketamine had 
amplified Lactobacillus, Turicibacter and Sarcina and decreased opportunistic 
pathogens Mucispirillum and Ruminococcus compared to mice that received saline 
(Getachew et al., 2018). Phencyclidine, another NMDA receptor antagonist, causes 
hyperlocomotion, social withdrawal and cognitive impairment in rodents. Sub-
chronic phencyclidine (subPCP) treatment altered cognition and gut microbiota 
composition in rodents, whereas administration of ampicillin abolished the subPCP-
induced memory deficit (Pyndt Jorgensen et al., 2015).  
 
A preclinical study showed a decrease in the NMDAR subunit NR2B mRNA 
expression in the amygdala in GF mice (Neufeld et al., 2011). The prebiotics galacto-
oligosaccharide (B-GOS) and fructo-oligosaccharide (FOS) elevated NMDAR 
subunits, implicated in synaptic plasticity, in the hippocampus, with B-GOS 
additionally increasing NR2A subunits in this region, and NR1 and D-serine in the 
frontal cortex (Savignac et al., 2013). B-GOS administration to rats improved 
performance in a set-shifting task, associated with an increase in cortical NMDA 
receptor function (Gronier et al., 2018). 
 
A recent FMT study showed that gut microbiome transfer from individuals with 
schizophrenia to GF mice modulated the glutamate-glutamine-GABA cycle 
associated with increased startle responses and locomotor hyperactivity (Zheng et al., 
2019a). This study found elevated glutamine in the serum and hippocampus and 
decreased glutamate (glutamic acid) in the stool and hippocampus, in GF mice that 
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received an FMT from schizophrenia patients compared to health controls (Zheng et 
al., 2019a). This study also showed that GABA, known to be dysfunctional in 
schizophrenia (Schmidt and Mirnics, 2015), was increased in the hippocampus in GF 
mice that received the FMT from schizophrenia patients (Zheng et al., 2019a). 
Preceding preclinical studies showed L. rhamnosus (JB-1) increased GABA receptor 
levels in the hippocampus in mice (Bravo et al., 2011) and increased central GABA 
levels as measured non-invasively by magnetic resonance spectroscopy (MRS)  
(Janik et al., 2016). However, unfortunately L. rhamnosus has not, as yet, translated 
into the clinic (Kelly et al., 2017a, Kelly et al., 2016b, Kelly et al., 2019a). Prebiotics 
can also alter GABA in animal models. Fructo-oligosaccharide (FOS) and galacto-
oligosaccharide (GOS), increased GABA-B1 and GABA-B2 receptor gene expression 
in the hippocampus (Burokas et al., 2017).  
 
The parasitic protozoan Toxoplasma gondii, known to alter the gut microbiota 
(Molloy et al., 2013) is associated with an increased risk of schizophrenia (Torrey and 
Yolken, 2003, Severance et al., 2016a, Monroe et al., 2015, Bhadra et al., 2013). 
Latent T. gondii can upregulate cerebral complement factor C1q (Xiao et al., 2016), 
alter dopamine metabolism (Prandovszky et al., 2011) and is associated with reduced 
psychomotor performance (Beste et al., 2014, Havlicek et al., 2001). A translational 
study showed that T. gondii infection produced sustained, strain-specific, anti-
NMDAR immune responses, in conjunction with alterations in surrogate markers of 
blood-gut (gluten IgG) and BBB (S100B) function in mice (Kannan et al., 2017). In 
the human part of the same study, NMDAR IgG and markers of barrier permeability 
were significantly associated with T. gondii exposure in subgroups of individuals 
with schizophrenia compared with controls, independently of antipsychotic 
medication (Kannan et al., 2017). 
 
Brain-Derived Neurotrophic Factor (BDNF) 
A key regulator of synaptic plasticity and neurogenesis in the brain, throughout life, 
is the neurotrophin BDNF (Monteggia et al., 2004). Given the role of BDNF in the 
regulation of synaptic strengthening and pruning, maintaining appropriate levels of 
BDNF and other neurotrophins, especially during critical neurodevelopmental 
windows is vital for schizophrenia (Nieto et al., 2013). Meta-analysis showed reduce 
blood levels in both medication naïve and medicated adult individuals diagnosed 
with schizophrenia (Green et al., 2011). Preclinical studies show that BDNF levels are 
influenced by the gut microbiota (Table 2).  
 
Serotonin (5-HT) and Kynurenine pathway 
The indolamine 5-HT has a wide range of physiological functions, including anxiety 
and fear modulation, stress responsivity, reward, cognition and social behaviour 
(Asan et al., 2013, Dayan and Huys, 2008, Lucki, 1998). In schizophrenia, a meta-
analysis of post-mortem studies found an elevation in prefrontal 5-HT1A receptors 
and a reduction in prefrontal 5-HT2A receptors (Selvaraj et al., 2014). The largest 
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reserve of 5-HT is located in enterochromaffin cells in the GIT (Berger et al., 2009), 
where 5-HT plays an important role in secretion, sensing and signalling (Mawe and 
Hoffman, 2013). 5-HT, and its precursor tryptophan, are critical signalling molecules 
in the MGB axis and under the influence of gut microbiota, especially, but not limited 
to, periods prior to the emergence of a stable adult-like gut microbiota (O'Mahony et 
al., 2015, Clarke et al., 2013, Desbonnet et al., 2008, El Aidy et al., 2012, Hata et al., 
2017) (Table 2). A metabolomics study showed a three-fold increase in plasma 
serotonin levels when GF mice were colonized by gut microbiota (Wikoff et al., 
2009). Bacterial metabolites, such as SCFA’s can increase tryptophan hydroxylase 1 
transcription, the rate limiting for mucosal 5-HT synthesis in chromaffin cell cultures 
(Reigstad et al., 2015) and increase colonic and blood 5-HT in GF mice (Yano et al., 
2015).  
 
The regulation of circulating tryptophan availability, and the distribution and 
subsequent kynurenine pathway metabolism, in the periphery and CNS, is tightly 
regulated during all stages of life (Badawy, 2017, Ruddick et al., 2006, Kennedy et al., 
2017). The enzyme indoleamine 2,3-dioxygenase (IDO) found in macrophages and 
microglia cells is the first and rate limiting step in the kynurenine pathway of 
tryptophan catabolism. The expression of tryptophan-2,3-dioxygenase (TDO) can be 
induced by circulating glucocorticoids (O'Connor et al., 2009) and has been reported 
to be regulated by the gut microbiota during colonization (El Aidy et al., 2014). 
Under normal physiological conditions, approximately 99% of tryptophan is 
metabolized to kynurenine in the liver by TDO. However, proinflammatory 
cytokines, known to be associated with schizophrenia (discussed above) can induce 
IDO resulting in the metabolism of tryptophan along the kynurenine pathway 
(Schwarcz et al., 2012). Kynurenine, tryptophan and 3-hydroxykynurenine (3-HK) 
can cross the BBB and tryptophan’s conversion to kynurenine and 3-HK in the 
peripheral circulation can therefore contribute to CNS levels (Schwarcz et al., 2012, 
Myint and Kim, 2014). In the brain, the end result of the metabolic pathway in 
astrocytes is Kynurenic acid (KYNA) (Gramsbergen et al., 1997), whereas, in 
microglia, it is quinolinic acid (Alberati-Giani et al., 1996). A recent study in mice 
exposed to chronic social defeat stress, known to increase colitis susceptibility, 
showed an accumulation of KYNA in the gut, which activated protein-coupled 
receptor 35 (GPR35) signalling to induce autophagy-dependent degradation of 
NLRP3 in macrophages, leading to IL-1β production (Zheng et al., 2019b). 
 
The regulation of the kynurenine pathway is important throughout life, but especially 
during sensitive periods of early neurodevelopment (Notarangelo et al., 2019). 
Abnormal KYNA levels are implicated in the pathophysiology of schizophrenia. 
KYNA is an NMDA and alpha7 nicotinic (α7nACh) receptor antagonist, both 
important in modulating brain development with implications for cognition, social 
behaviour and anxiety-like behaviour (Myint and Kim, 2014, Pershing et al., 2015, 
Pocivavsek et al., 2014, Notarangelo and Pocivavsek, 2017, Pershing et al., 2016, 
Forrest et al., 2015, Erhardt et al., 2016, Notarangelo and Schwarcz, 2017). In 
schizophrenia, increased KYNA levels in the CSF, including in drug naïve patients 
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(Nilsson et al., 2005), and in post-mortem brain samples have been shown (Erhardt 
et al., 2001, Plitman et al., 2017). Furthermore, the plasma kynurenine/tryptophan 
ratio was significantly higher in patients diagnosed with schizophrenia (n=34) 
compared to healthy controls (n=36) (Barry et al., 2009). In a clinical study, patients 
with schizophrenia (n=64) were more intolerant to a psychological stress challenge 
than healthy controls, and while salivary KYNA levels increased significantly between 
baseline and 20 minutes following the stressor in both groups, patients who were 
unable to tolerate the stressful tasks showed significantly higher levels of KYNA, 
compared to patients who tolerated the psychological stressor or healthy controls 
(Chiappelli et al., 2014).  
 
In a recent post-mortem study, the kynurenine/tryptophan ratio, KYNA levels, and 
TDO mRNA and kynurenine aminotransferases (KATI/II) mRNA, were significantly 
increased in the PFC in the schizophrenia subgroup with high cytokine mRNA levels 
(Kindler 2019). In plasma, the high cytokine schizophrenia subgroup displayed an 
elevated kynurenine/tryptophan ratio, which correlated inversely with attention and 
dorsolateral prefrontal cortex (DLPFC) volume (Kindler et al., 2019). Collectively, 
these preclinical and clinical studies highlight the importance of the kynurenine 
pathway during neurodevelopment with the associated implications for 
schizophrenia. Exploration of the microbial regulation of this pathway is emerging as 
an important objective in schizophrenia research. 
 
Short Chain Fatty Acids (SCFA’s) 
SCFA’s (butyrate, acetate and propionate) are neurohormonal signalling molecules 
produced by microbial fermentation of indigestible dietary fibres. SCFAs can reach 
the circulation, cross the BBB (Frost et al., 2014, Vijay and Morris, 2014, Steele, 
1986) and have a wide range of physiological functions (Koh et al., 2016). Butyrate,  
in addition to functioning as a ligand for a subset of G protein-coupled receptors 
(Bourassa et al., 2016), acts as a potent inhibitor of Histone deacetylases (HDACs). 
Histone acetylation initiates or assists in chromatin relaxation, allowing access of the 
transcription mechanisms to specific positions. Conversely, HDACs inhibit this 
transcriptional activity due to the enhanced binding of histones to the DNA structure 
(chromatin condensation). HDAC inhibition has been proposed as a mechanism by 
which the microbiota via SCFA production may act as a mediator of gene-
environment interactions (Stilling et al., 2016a, Stilling et al., 2014). While the 
physiological levels of SCFAs may be subtle, cumulative chronic delivery may 
produce long-lasting stable effects on gene expression (Stilling et al., 2014). 
 
Post-mortem analysis of human brain tissue showed that HDAC1 levels are elevated 
in the PFC and hippocampus of patients with schizophrenia (Sharma et al., 2008, 
Benes et al., 2007). Similarly, HDAC1 mRNA and protein levels were elevated in the 
PFC of patients with schizophrenia and in blood from patients with schizophrenia 
who had experienced early life stress (Bahari-Javan et al., 2017). In the preclinical 
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arm of the same study, mice subjected to a maternal separation paradigm, had 
increased HDAC1 levels in the PFC, which were associated with deficits in novel 
object recognition and prepulse inhibition (Bahari-Javan et al., 2017). In addition, 
the administration of an HDAC inhibitor (MS-275) ameliorated some of the early life 
stress-induced behavioural deficits. It would be interesting to determine whether 
SCFA’s could also ameliorate these schizophrenia-like behavioural deficits. It has 
previously been shown that supra-physiological levels of SCFA’s produce marked 
deficits in cognitive performance, social interaction and locomotor activity in rodents 
(Macfabe, 2012, MacFabe et al., 2007, Thomas et al., 2012). More recently, 
administration of a mixture of acetate, propionate and butyrate, to mice, following a 
3-week social defeat and overcrowding procedure, alleviated heightened stress-
responsiveness and stress-induced increases in intestinal permeability, while also, 
decreasing anxiety-like behaviour in the open field test and decreasing depressive-
like behaviour in the forced swim test (van de Wouw et al., 2018). 
 
Microbiota and Social Behaviour  
The PFC, the amygdala and temporoparietal junction form key components of the 
neural circuitry underlying social cognition and behaviour and have been shown to 
be abnormal in people with schizophrenia (Rasetti et al., 2009, Aleman and Kahn, 
2005). The amygdala, vital for social behaviour, acts as an emotional salience 
encoder. Schizophrenia is associated with decreased activation of the amygdala to 
emotional stimuli (Aleman and Kahn, 2005) and decreased interactions between the 
amygdala and the medial PFC (Williams et al., 2004). The amygdala is particularly 
sensitive to changes in microbiome composition (Cryan and Dinan, 2018, Cowan et 
al., 2018). In GF mice, amygdala neuronal activity (Stilling et al., 2015) and dendritic 
morphology is altered (Luczynski et al., 2016). In these mice, expression of 
immediate early response genes such as Fos, Fosb, Egr2 or Nr4a1 were increased in 
the amygdala, in conjunction with increased signalling of the transcription factor 
CREB (Stilling et al., 2015). Differential expression and recoding of several genes 
involved in fundamental brain processes ranging from neuronal plasticity, 
metabolism, neurotransmission and morphology were identified and a significant 
downregulation was noted for immune system-related genes (Stilling et al., 2015). 
Moreover, GF mice show attenuated social stimulus-dependent transcriptional 
regulation in the amygdala, and an increase in expression of splicing factors and 
exon usage, compared to control mice (Stilling et al., 2018). Additionally, 
myelination, a process tentatively linked to brain dysconnectivity in schizophrenia 
(Konrad and Winterer, 2008, Hakak et al., 2001, Mighdoll et al., 2015, Kelly et al., 
2018), is partially under the influence of the gut microbiota (Hoban et al., 2016b). GF 
mice exhibited an upregulation of genes linked to myelination and myelin plasticity, 
with hyper-myelinated axons within the PFC (Hoban et al., 2016b).  
 
At the behavioural level, GF mice display abnormal social behaviours, including 
social motivation and social novelty preference (Desbonnet et al., 2014). This 
decreased sociability has been reproduced in GF rats (Crumeyrolle-Arias et al., 
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2014). In addition to an altered transcriptional profile in the amygdala, GF mice have 
been shown to exhibit reduced freezing behaviour during a cued amygdala-
dependent memory retention test, while colonized GF mice were behaviourally 
comparable to conventionally raised mice during the memory retention test (Hoban 
et al., 2017). In a recent FMT study, GF mice transplanted with gut microbiota from 
schizophrenia patients, displayed locomotor hyperactivity, decreased anxiety and 
depressive-like behaviours, and increased startle responses (Zheng et al., 2019a).  
 
The urban environment has long been regarded as a risk factor for the development 
of psychotic disorders (Table 1) (Vassos et al., 2012, Pedersen and Mortensen, 2001, 
Krabbendam and van Os, 2005, Peen et al., 2010, Newbury et al., 2016, Omer et al., 
2016). However, a recent meta-analysis showed that this elevated risk may not apply 
to developing countries and highlighted the variable urban-rural patterns of cannabis 
use, racial discrimination, and socioeconomic disparities between developing and 
developed nations (DeVylder et al., 2018). In healthy controls, current city living was 
associated with increased amygdala activity, whereas urban upbringing affected the 
perigenual anterior cingulate cortex (ACC) (Lederbogen et al., 2011). Alterations in 
gray matter volume in the right DLPFC and in the perigenual ACC have also been 
associated with urban upbringing (Haddad et al., 2015). Moreover, urban upbringing 
leaves an immunoregulatory imprint. Healthy controls with an urban upbringing, 
without exposure to pets, was associated with a more pronounced increase in the 
number of peripheral blood mononuclear cells and plasma IL-6 concentrations, 
following acute psychosocial stress induced by the Trier social stress test, compared 
to rural upbringing in the presence of farm animals (Böbel et al., 2018).  
 
Urbanisation is also associated with an increased risk of immune and metabolic 
disorders, including obesity, while reducing microbial diversity and impacting the 
overall functionality of the gut microbiome (Mancabelli et al., 2017, Clemente et al., 
2015, Yatsunenko et al., 2012, Sonnenburg and Sonnenburg, 2019). Whether 
differential environmental exposure to microbes in the urban compared to the rural 
environment interact with differences in social stressors to alter social stress neural 
circuitry remains to be seen (Stamper et al., 2016). Similarly, unravelling the 
microbial mediated contribution to social stress related to migration, another risk 
factor for schizophrenia (Cantor-Graae and Selten, 2005) is an intriguing endeavour. 
A recent study showed that migration from a non-Western country to the United 
States was associated with immediate loss of gut microbiome diversity and function 
(Vangay et al., 2018). Specifically, bacterial enzymes associated with plant fiber 
degradation, and a displacement of Prevotalla with Bacteroides strains occurs over 
time (Vangay et al., 2018). It is interesting to note that Zheng and colleagues showed 
that individuals with schizophrenia had reduced gut microbiota alpha diversity 
compared to healthy controls (Zheng 2019), echoing the concept that a more diverse 
ecosystem may be a health promoting factor (Dantzer et al., 2018). Whether a more 
diverse microbial biodiversity, with its corresponding MGB axis signalling, especially 
during specific vulnerable neurodevelopmental periods has implications for the 
trajectory of schizophrenia remains to be seen.  
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Microbiota and Cognition 
Social cognition is just one of the multiple cognitive domains that are impaired in 
schizophrenia (Kahn and Keefe, 2013). Evolving cognitive activity during 
neurodevelopment is dependent on the microbiota and its metabolic outputs 
(Sordillo et al., 2019, Fouhy et al., 2019). The combination of acute stress and 
infection can impact cognition. Citrobacter rodentium infected C57BL/6 mice that 
were exposed to acute stress exhibited memory dysfunction (Gareau et al., 2011). 
Moreover, GF Swiss-Webster mice displayed memory impairment at baseline, in the 
absence of acute stress (Gareau et al., 2011). In male C57BL/6 mice, higher 
percentages of Clostridiales and lower levels of Bacteroidales in high-energy diets 
were related to the poorer cognitive flexibility (Magnusson et al., 2015). In BALB/c 
mice, treatment with B. Longum resulted in an improvement in stress related 
behaviour and cognition (Savignac et al., 2015).  
 
Hippocampal volume reduction is associated with schizophrenia (Velakoulis et al., 
2006, Adriano et al., 2012). Indeed, hippocampal neurogenesis, a pivotal process in 
learning and memory consolidation (Deng et al., 2010, Hueston et al., 2017, Levone 
et al., 2015, Anacker and Hen, 2017) has been shown to be regulated by the gut 
microbiota, mediated at least partially via the vagus nerve. Subdiaphragmatic 
vagotomised adult male BALB/c mice had decreased BDNF mRNA, reduced 
proliferation and survival of newly born cells and a decreased number of immature 
neurons in the hippocampus  (O’Leary et al., 2018). FMT from mice exposed to 
unpredictable chronic mild stress, to antibiotic treated mice, showed decreased adult 
hippocampal neurogenesis and depressive-like behaviours compared to mice that 
received non-stressed FMT (Siopi et al., 2019). Moreover, subdiaphragmatic 
vagotomy abolished the microbiota-induced effects on behaviour and neurogenesis 
(Siopi et al., 2019). GF mice exhibit increased adult hippocampal neurogenesis in the 
dorsal hippocampus, and post-weaning microbial colonisation failed to reverse the 
changes in adult hippocampal neurogenesis (Ogbonnaya et al., 2015). Furthermore, 
exercise or probiotics were able to ameliorate deficits in neurogenesis and behaviour 
in antibiotic-treated mice (Mohle et al., 2016). L. johnsonii CJLJ103 attenuated 
memory impairment and colitis in mice by inhibiting gut microbiota 
lipopolysaccharide production and NF-κB activation (Lim et al., 2017).  
 
Antibiotic-induced alterations of the microbiota-gut-brain axis also modulate 
cognition. Using an antibiotic (ampicillin, metronidazole, vancomycin, ciprofloxacin, 
imipenem) treated rat model, gut microbiota depletion during adulthood resulted in 
deficits in spatial memory as measured by the Morris water maze (Hoban et al., 
2016a). In another preclinical antibiotic study (ampicillin, bacitracin, meropenem, 
neomycin, and vancomycin), novel object recognition, but not spatial memory, was 
impaired in the antibiotic-treated mice and this cognitive deficit was associated with 
brain region-specific changes in the expression of BDNF, NMDAR subunit NR2B, 
serotonin transporter and neuropeptide Y system (Frohlich et al., 2016).  
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Clinical Schizophrenia studies and gut microbiota  
Several preliminary clinical studies investigating the microbiome across the different 
stages of schizophrenia, from at risk states to FEP to established schizophrenia, have 
emerged (Table 3). The most recent study showed that patients with schizophrenia 
(n=63) had lower alpha (within-sample) diversity compared to health controls 
(n=69), and that several species (Aerococcaceae, Bifidobacteriaceae, Brucellaceae, 
Pasteurellaceae, and Rikenellaceae) reportedly discriminated individuals from 
healthy controls (Zheng et al., 2019a). As well as, demonstrating the gut microbiota’s 
influence over amino acid pathways in schizophrenia (discussed above), this study 
showed altered lipid metabolism in serum and hippocampus in GF mice that 
received the FMT from a random sample of five schizophrenia patients (Zheng et al., 
2019a). Specifically, glycerophospholipids including phosphatidylethanolamines, 
phosphoserines, phosphatidylcholines and phosphatidylinositol were all decreased. 
Interestingly, recent data from the Avon Longitudinal Study of Parents and Children, 
showed that dysregulated blood phosphatidylcholines and lysophosphatidylcholines 
at age 12 years, contributed to psychotic experiences at age 18 years (Madrid-Gambin 
et al., 2019). It would be an appealing prospect to decipher the mediating role of the 
gut microbiota in this sample.  
 
A recent study showed increased abundances of Clostridiales, Prevotella and L. 
ruminis in fecal samples, in an ultra-high-risk (UHR) group (n=19) compared to 
health controls (He 2018). Levels of choline measured by MRS in the ACC were also 
elevated in the UHR group compared to the healthy control group. There were no 
significant differences between the high-risk group and healthy group (He 2018). In 
people diagnosed with FEP (n = 28), the of majority of whom were prescribed 
antipsychotics, there were significantly increased Lactobacillaceae and decreased 
Veillonellaceae at the family level and increased Lactobacillus at the genus level 
compared to healthy controls (n = 16) (Schwarz et al., 2018). This decrease in 
Veillonellaceae in FEP contrasts with the increase in the Zheng et al study. The 
authors report that Lactobacillus group bacterial numbers correlated positively with 
severity of psychotic symptoms measured using the Brief Psychiatric Rating Scale, 
and negatively with global assessment of functioning scale. Lactobacilli and 
Lactobacilli phage phiadh were also found in greater abundances in the 
oropharyngeal microbiome in people diagnosed with schizophrenia (Castro-Nallar et 
al., 2015, Yolken et al., 2015).  
 
Translation: 
Will definitive developments that will impact patient care emerge? There has been 
one clinical interventional study investigating probiotics in patients diagnosed with 
schizophrenia (Table 3). This 14-week, randomized, double-blind, placebo-
controlled trial (n = 65), used L. rhamnosus strain GG and B. animalis subsp. lactis 
strain Bb12, added to antipsychotic treatment as usual (Dickerson et al., 2014). The 
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probiotics improved GI symptoms, and increased levels of serum BDNF (Tomasik et 
al., 2015), but failed to impact positive or negative symptoms (Dickerson et al., 
2014). However, male participants in the probiotic group had significantly reduced C. 
albicans antibodies and there was a trend towards improvement in the Positive and 
Negative Syndrome Scale (PANSS) positive symptom subset score in seronegative 
males (Severance et al., 2017). In contrast, the same research group, randomized 
patients hospitalized for a manic episode (n=66), to receive 24 weeks of adjunctive 
probiotics (L. rhamnosus strain GG and B. animalis subsp. lactis strain Bb12) or 
adjunctive placebo at discharge (Dickerson et al., 2018). The probiotic group had 
lower rates of re-hospitalization compared to the group that received the placebo. 
 
Antipsychotics: 
Antipsychotics alter the gut microbiota and the metabolic side-effects of commonly 
used antipsychotics are at least partially mediated by the gut microbiota (Cussotto et 
al., 2018, Cussotto et al., 2019, Dinan and Cryan, 2018, Maier et al., 2018, Nehme et 
al., 2018). In a preclinical study, chronic olanzapine treatment altered gut microbiota 
composition and induced significant body weight gain in female rats, while both 
males and females had olanzapine-induced increases in adiposity (Davey et al., 
2012). Pre-treatment with an antibiotic cocktail attenuated this weight gain (Davey et 
al., 2013). Another study using GF mice, demonstrated that the gut microbiota is 
necessary and sufficient for weight gain caused by oral olanzapine, which shifted the 
microbiota profile towards an "obesogenic" bacterial profile (Morgan et al., 2014). 
Weight gain was attenuated when olanzapine was co-administered with prebiotics. 
B-GOS, known to induce the growth of beneficial bacteria, including Bifidobacteria, 
reduced weight gain in olanzapine treated rats (Kao et al., 2018). 
 
Similarly, FMT from risperidone-treated mice to risperidone naive recipients 
resulted in a 16% reduction in total resting metabolic rate (Bahra et al., 2015). The 
same research group translated the findings into an adolescent clinical cohort to 
show that chronic risperidone treatment was associated with an increase in body 
mass index and a significantly lower ratio of Bacteroidetes:Firmicutes compared to 
antipsychotic-naive psychiatric controls (Bahr et al., 2015). In first episode 
schizophrenia, 24 weeks of risperidone resulted in weight gain, increased C-reactive 
protein, increased fasting lipids and glucose and gut microbiota changes (Yuan et al., 
2018). Another clinical study of atypical antipsychotics in bipolar affective disorder 
(n=117), showed overall differences in Lachnospiraceae, Akkermansia, and 
Sutterella, and decreased species richness in female antipsychotic treated patients 
(Flowers et al., 2017).  
 
There is growing interest in the influence of the microbiome on drug metabolism and 
absorption (Clarke et al., 2019, Zimmermann et al., 2019). An elegant study 
highlighting the role of gut microbiota metabolism in drug availability, showed gut 
bacterial tyrosine decarboxylases modulated levels of levodopa in Parkinson’s disease 
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(van Kessel et al., 2019). Indeed, we look forward to the results of a translational 
study, currently underway in Toronto, investigating the interaction of the gut 
microbiome and clozapine (Gorbovskaya et al., 2019).  
 
The antibiotic minocycline, notwithstanding a complex mechanism of action, is 
known to modulate the MGB axis (Wong et al., 2016). Preliminary studies of this 
antibiotic showed potential in reducing negative and cognitive symptoms in 
schizophrenia (Levkovitz et al., 2010, Miyaoka et al., 2008, Khodaie-Ardakani et al., 
2014, Jhamnani et al., 2013). Disappointingly, a recent well-powered (n=207) RCT of 
minocycline augmentation, in early stage schizophrenia spectrum disorder, did not 
impact symptoms or biomarkers (Deakin et al., 2018). However, it is important note 
that minocycline reduces gut microbiome diversity and does not preclude future 
studies of microbiome-based therapies in the form of prebiotics, live biotherapeutics 
or small molecules in the amelioration of cognitive or negative symptoms in 
subgroups with psychosis spectrum disorder. 
 
Conclusions and Perspectives 
The term schizophrenia, traditionally reserved for the severe end of the psychosis 
spectrum, is not a unified entity (Anttila et al., 2018, Jauhar et al., 2017, Hulshoff Pol 
et al., 2012) and is associated with stigma, negative bias and public mis-
understanding (Takahashi et al., 2009). Unravelling the mysteries of schizophrenia 
will require a systems level dimensional approach, incorporating the impact of 
genetics and environmental inputs throughout the neurodevelopmental trajectory. 
Considering the microbiome contributes to the modulation of many of the processes 
during neurodevelopment, including neurogenesis, myelination, dendrite formation 
and blood brain barrier development and plays a role in cognitive function, social 
interaction, locomotor activity and stress management, the integration of the 
microbiome as an additional unit of analysis in the evolving dimensional framework, 
may provide a more complete understanding of the neurobiological architecture of 
this complex condition (Insel et al., 2010, Severance et al., 2016b, Kahn et al., 2015, 
Kelly et al., 2017b) (Table 4).  
 
Deconstructing heterogenous traditional categorical diagnoses into dimensions, to 
uncover the interaction of biological mechanisms with environmental inputs is 
particularly challenging in the trajectory of psychosis spectrum disorders but may 
offer potential to advance the precision-personalized-preventative health framework 
(Ford et al., 2014, Cohen et al., 2017, Reininghaus et al., 2016a, Öngür, 2017, 
Silbersweig and Loscalzo, 2017). In other areas of medicine, the integration of the gut 
microbiome into predictive models using machine learning techniques has been 
shown to be clinically useful, for example; predicting post-prandial glucose levels 
(Zeevi, David 2015), steady-state plasma glucose (a measure of peripheral insulin 
resistance) (Schüssler-Fiorenza Rose et al., 2019) and triglyceride levels and high-
density lipoproteins (Fu et al., 2015). In keeping with this advance towards a 
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precision-personalized-preventative health strategy, probiotics have also been shown 
to have an individualized impact on mucosal community structure and gut 
transcriptome (Zmora et al., 2018, Johnson et al., 2019).  
 
While emerging preliminary clinical studies suggest that an altered gut microbiota is 
physiologically relevant in schizophrenia, the full neuropsychiatric implications of 
subtle alterations in MGB axis signalling, at early developmental stages or during 
adolescence have yet to be fully explored. For example, do microbial signature 
aberrations serve as additional risk factors or mediators in the development of 
psychotic disorders or in conjunction with stress, as contributory triggers for 
psychotic relapse? Or could the microbiota signature aberration occur early but 
remain clinically silent? Could a microbial based therapy reduce conversion to 
psychosis in subgroups at risk of developing the disorder. Furthermore, diet-
microbiota and drug-microbiota interactions in psychosis are promising avenues of 
clinical research (Table 5).  
 
It is perhaps not surprising that a consistent microbial biosignature has not emerged. 
There are notable limitations in the clinical studies (Table 3). The vast majority of 
participants were prescribed antipsychotic medication, which as discussed above, 
can alter gut microbiota composition. Furthermore, detailed dietary information is 
lacking. However, the most problematic issue relates to sample size. Well powered, 
longitudinal studies, including medication free individuals, and detailed dietary 
analysis, encompassing neuroimaging markers would be required to determine if 
targeting the MGB axis signalling system by psychobiotic strategies (probiotics, 
prebiotics, diet) translates into clinical utility. This will require functional and 
compositional microbiome analysis and standardised specimen preparation and 
analytical protocols (Costea et al., 2017). Pioneering the nascent field of microbiome 
research has potential to contribute to the evolution of precision-personalized-
preventative psychiatry. 
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